Upgrade to SI Premium - Free Trial

RBC on Pfizer (PFE): 'Litigation overhang cleared'

April 28, 2026 9:46 AM
RBC Capital analyst Trung Huynh reiterated an Underperform rating and $25.00 price target on Pfizer (NYSE: PFE).The analyst comments "Our ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles